| Literature DB >> 32419549 |
Antti Turunen1,2, Jaakko Valtola1,3, Anu Partanen1, Antti Ropponen4, Outi Kuittinen2,5,6, Hanne Kuitunen6, Kaija Vasala7, Lasse Ågren8, Karri Penttilä3,9, Leena Keskinen10, Eeva-Riitta Savolainen11, Marja Pyörälä1, Taru Kuittinen1, Tuomas Selander12, Pentti Mäntymaa13, Jukka Pelkonen4,13, Esa Jantunen1,2,8, Ville Varmavuo14.
Abstract
Autologous stem cell transplantation (auto-SCT) is an established treatment option in patients with non-Hodgkin lymphoma (NHL). In this prospective multicenter study, the effect of infused blood graft cellular composition on post-transplant outcome was analyzed in 129 NHL patients. Higher graft CD34+ cell content (>2.5 × 106/kg) correlated with better progression-free survival (PFS) (p=.009) and overall survival (OS) (p=.004). Higher graft CD34+CD133+CD38- counts (>0.08 × 106/kg) were also linked with better PFS (p=.03) and OS (p=.004), and these survival benefits retained in multivariate analyses. Higher infused CD3+CD4+ cell count (>37 × 106/kg) predicted better PFS (p=.013) and OS (p=.007) in multivariate analysis. Autograft cellular composition seems to impact outcome in NHL patients. These observations regarding composition of optimal graft in autologous setting should be validated in an independent patient series or in a randomized study.Entities:
Keywords: Non-Hodgkin lymphoma; autologous stem cell transplantation; flow cytometry; graft cellular composition; outcome
Mesh：
Year: 2020 PMID： 32419549 DOI： 10.1080/10428194.2020.1762879
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022